

Aldosterone Receptor Antagonists Market Is Reach to US\$ 4.5 Bn and Exhibit at a CAGR of 7.1% in the year 2031 | by TMR

Growth in number of patients suffering from conditions such as hypertension and heart failure is expected to drive aldosterone receptor antagonists market

WILMINGTON, DELAWARE, UNITED STATES, September 20, 2023 /EINPresswire.com/ -- Transparency Market Research - The Aldosterone Receptor Antagonists Market stood at USD 2.4 bn in 2022 and it is expected to reach USD 4.5 bn by 2031 with CAGR of 7.1%. Rapid increase in usage of mineralocorticoid-receptor antagonists (mra) to treat patients with heart failure and various forms of hypertension, such as resistant hypertension, is expected to augment the global aldosterone receptor antagonists market. Therapies based on aldosterone receptor antagonists



are likely to become popular to treat cardiovascular diseases.

Adoption of aldosterone receptor antagonist agents to improve renal function has increased significantly among patients suffering from chronic kidney diseases. These drugs work primarily by blocking epithelial and non-epithelial actions of aldosterone. These are effective in improving cardiovascular prognosis in patients after myocardial infarction. Rise in utilization of medications in tablet form is expected to augment the aldosterone receptor antagonists market outlook. Recent advances in third-generation MR antagonists are likely to bolster the market in the near future.

The healthcare industry is keen on reducing the cost of medications based on aldosterone receptor antagonists in order to make these affordable to people especially in low- and middle-income countries. Significant adoption of steroidal MRAs to treat and manage patients with heart failure is fueling the aldosterone receptor antagonists market industry. Increase in adoption is ascribed to availability of generic medicines based on steroidal MRAs. Key Drivers

Rise in elderly population is driving the demand for drugs based on aldosterone receptor antagonists to treat heart failure and resistant hypertension. A few mineralocorticoid-blocking agents have been extensively utilized as a therapy to reduce blood pressure.

High prevalence of hypertension and heart failure in populations globally is expected to bolster the aldosterone receptor antagonists market development

Continuous advancements in drugs have led to availability of medications that effectively reduce the biological effects of aldosterone in the patient population and improve cardiovascular outcomes.

Companies Profiled:

- RPG Life Sciences Limited (RPG Group)
- Bayer AG
- CMP Pharma
- AdvaCare Pharma
- Gedeon Richter Plc.
- Sanofi
- INTRA INVENTURE
- A-S Medication Solutions, LLC
- Viatris Inc. (Mylan N.V.)

https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=85448

Aldosterone Receptor Antagonists Market Segmentation

Drug Type

- Steroidal Mineralocorticoid Receptor Antagonists
- Non-steroidal Mineralocorticoid Receptor Antagonists

Dosage Form

- Tablets
- Suspensions
- Capsules
- · Creams & Gels

Indication

- Hypertension
- Heart Failure
- Edema
- Primary Aldosteronism
- Others

Distribution Channel

- Hospital Pharmacies
- Online Pharmacies
- · Retail Pharmacies

- North America (the United States, Canada, and Mexico)
- Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
- Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))
- South America (Brazil etc.) The Middle East and Africa (North Africa and GCC Countries)

0000 000 00000? 000 00 0000000:

https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=85448

- What are some of the recent brand building activities of key players undertaken to create customer value in the Aldosterone Receptor Antagonists market?
- Which companies are expanding litany of products with the aim to diversify product portfolio?
- Which companies have drifted away from their core competencies and how have those impacted the strategic landscape of the Aldosterone Receptor Antagonists market?
- Which companies have expanded their horizons by engaging in long-term societal considerations?
- Which firms have bucked the pandemic trend and what frameworks they adopted to stay resilient?
- What are the marketing programs for some of the recent product launches?

<u>Hyperthermia Cancer Treatment Market</u>: Hyperthermia is a form of therapy where heat is used to enhance effectiveness of radiation and chemotherapy, and to destroy tumors. Hyperthermia

is most often used to treat tumors that are close to the surface of the body.

<u>Bioresorbable Vascular Scaffold Market</u>: Bioresorbable vascular scaffold (BVS) is a medical device that can be used to treat coronary artery disease. It is a type of stent made of a biodegradable polymer material that dissolves over time, leaving behind only the natural vessel.

Nikhil Sawlani Transparency Market Research Inc. +18665523453 ext. email us here Visit us on social media: Twitter LinkedIn

YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/656586271

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2023 Newsmatics Inc. All Right Reserved.